HC Wainwright Reaffirms Buy Rating for TG Therapeutics (NASDAQ:TGTX)

HC Wainwright reiterated their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $45.00 price objective on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on TGTX. B. Riley boosted their price target on shares of TG Therapeutics from $24.00 to $29.00 and gave the company a buy rating in a research report on Monday, February 5th. StockNews.com lowered shares of TG Therapeutics from a buy rating to a hold rating in a research report on Saturday, February 24th. Finally, The Goldman Sachs Group boosted their price target on shares of TG Therapeutics from $12.00 to $13.00 and gave the company a neutral rating in a research report on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average target price of $29.00.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock opened at $13.99 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 5.18 and a current ratio of 5.92. The firm’s 50-day simple moving average is $15.13 and its 200-day simple moving average is $13.87. TG Therapeutics has a twelve month low of $6.46 and a twelve month high of $35.67. The firm has a market cap of $2.16 billion, a P/E ratio of 699.85 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.03. TG Therapeutics had a net margin of 5.42% and a return on equity of 12.89%. The business had revenue of $43.97 million for the quarter, compared to analyst estimates of $40.06 million. During the same period in the previous year, the business earned ($0.39) EPS. As a group, research analysts expect that TG Therapeutics will post -0.12 EPS for the current fiscal year.

Insiders Place Their Bets

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of the business’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $15.97, for a total value of $351,340.00. Following the completion of the transaction, the director now directly owns 215,229 shares of the company’s stock, valued at $3,437,207.13. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors have recently modified their holdings of TGTX. Pingora Partners LLC bought a new position in shares of TG Therapeutics in the fourth quarter worth about $27,000. PNC Financial Services Group Inc. raised its stake in shares of TG Therapeutics by 131.7% in the third quarter. PNC Financial Services Group Inc. now owns 3,543 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 2,014 shares during the last quarter. Macquarie Group Ltd. raised its stake in shares of TG Therapeutics by 102.3% in the second quarter. Macquarie Group Ltd. now owns 10,190 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 5,152 shares during the last quarter. Coppell Advisory Solutions LLC bought a new stake in shares of TG Therapeutics during the second quarter worth approximately $46,000. Finally, KBC Group NV bought a new stake in shares of TG Therapeutics during the fourth quarter worth approximately $54,000. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.